publicações selecionadas
-
artigo de revista
- Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. Bioorganic & Medicinal Chemistry. 2015
- Antioxidant activity of aminodiarylamines in the thieno[3,2-b]pyridine series: Radical scavenging activity, lipid peroxidation inhibition and redox profile. Journal of Enzyme Inhibition and Medicinal Chemistry. 2014
- New di(hetero)arylethers and di(hetero)arylamines in the thieno[3,2-b]pyridine series: Synthesis, growth inhibitory activity on human tumor cell lines and non-tumor cells, effects on cell cycle and on programmed cell death. European Journal of Medicinal Chemistry. 2013
-
artigo de conferência
- Synthesis of new n-[3-(thieno[3,2-b]pyridine-7-ylthio)phenyl]benzamides as potential inhibitors of VEGFR2 using rational design 2013
- Epidermal growth factor receptor inhibitory activity of new potential antitumor di(hetero)arylethers and di(hetero)arylamines in the thieno[3,2-b]pyridine series 2013
- 1-Aryl-3-[ 4-( thieno[3,2-d]pyrimidin-4-yloxy )phenyl]ureas as VEG FR2 inhibitors: synthesis, docking enzymatic and cellular assays 2012
-
documento
- Antiangiogenic effects of new di(hetero)arylthioethers 1,3-diarylureas in the thieno[3,2-b]pyridine series. Role in VEGFR-2 inhibition. 2013
- New di(heteroaryl)thioethers 1,3-diarylureas in the thieno[3,2-b]pyridine series as VEGFR-2 tyrosine kinase inhibitors: docking, synthesis, enzymatic and celular assay. 2013